Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT06345482 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of MHB039A for Advanced Solid Tumor

Start date: April 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors.

NCT ID: NCT06332170 Not yet recruiting - Clinical trials for Advanced Solid Tumor

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.

NCT ID: NCT06302426 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Trial of INI-4001 in Patients With Advanced Solid Tumours

Start date: March 29, 2024
Phase: Phase 1
Study type: Interventional

Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.

NCT ID: NCT06298058 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

Start date: March 12, 2024
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A13 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).

NCT ID: NCT06289894 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of BRY805 in Participants With Advanced Solid Tumors

Start date: March 2024
Phase: Phase 1
Study type: Interventional

This is a phase 1 open label multicenter study to evaluate safety, tolerance and the maximum tolerance of BRY805 administered intravenously (IV) once every three weeks in participants with advanced solid tumors, so as to confirm the recommended phase 2 dose of BRY805 and obtain the preliminary efficacy information of participants with advanced solid tumors.

NCT ID: NCT06287463 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

NCT ID: NCT06277219 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

LIGHTSPEED-1
Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.

NCT ID: NCT06260774 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Start date: May 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors

NCT ID: NCT06260514 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Study of APR-1051 in Patients With Advanced Solid Tumors

ACESOT-1051
Start date: June 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.

NCT ID: NCT06257680 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors

Start date: February 18, 2024
Phase: Phase 1
Study type: Interventional

This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.